Hand–Foot Syndrome is a dose-dependent dermatologic side effect of several anticancer drugs. It primarily affects the palms of the hands and soles of the feet, areas exposed to pressure and friction.
It is not an allergic reaction — it results from chemotherapy drugs leaking from capillaries into the skin of the hands and feet, where they cause localized tissue damage.
Common Causative Agents
Targeted therapies (especially multikinase inhibitors) may cause a slightly different variant called hand–foot skin reaction (HFSR).
Clinical Presentation
Symptoms usually begin days to weeks after starting treatment:
Early signs:
- Tingling or burning sensation
- Redness (erythema)
- Mild swelling
- Increased sensitivity
Progressive symptoms:
- Painful swelling
- Blistering
- Peeling (desquamation)
- Cracking or ulceration (in severe cases)
Grading (CTCAE Classification)
Oncologists grade severity from 1 to 3:
- Grade 1: Minimal skin changes, no pain
- Grade 2: Skin changes with pain, affecting daily activities
- Grade 3: Severe pain, ulceration, inability to function normally
Grading determines whether chemotherapy is continued, reduced, or paused.
Pathophysiology
- Chemotherapy drug accumulates in capillaries of hands and feet
- Mechanical stress (pressure/friction) worsens damage
- Inflammation and keratinocyte injury occur
- Result → redness, pain, and skin breakdown
The high concentration of eccrine sweat glands in palms/soles may also contribute.
Prevention Strategies
- Avoid friction (tight shoes, excessive walking)
- Avoid heat exposure
- Use thick moisturizers (urea-based creams)
- Keep hands/feet cool during infusion (sometimes ice packs)
- Early symptom reporting
Management
Mild cases:
- Emollients
- Topical steroids
- Pain control
Moderate to severe:
- Dose reduction or temporary chemotherapy interruption
- Stronger topical steroids
- Oral analgesics
In severe cases, therapy may need modification.
Distinguishing HFS vs HFSR
| Feature | Classic HFS | HFSR (TKI-related) |
|---|---|---|
| Drugs | 5-FU, capecitabine | Sorafenib, sunitinib |
| Location | Diffuse palms/soles | Pressure points |
| Appearance | Symmetric redness | Localized callus-like lesions |
| Mechanism | Cytotoxic injury | Vascular + mechanical stress |
Clinical Relevance for Exams & Practice
In oncology boards and clinical settings, key associations include:
- Capecitabine → hand–foot syndrome
- Pegylated liposomal doxorubicin → high incidence
- TKIs → hand–foot skin reaction variant
- Management often requires dose modification